Biomarin Pharmaceutical (BMRN) Tax Provisions (2009 - 2026)

Biomarin Pharmaceutical has disclosed Tax Provisions across 18 years of filings, most recently posting $35.7 million for Q1 2026.

• Quarterly Tax Provisions fell 31.92% year-over-year to $35.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.9 million (down 22.32% YoY) and the FY2025 annual result came in at $133.6 million, up 16.25% from the prior year.
• Tax Provisions advanced to $35.7 million in Q1 2026, from $19.4 million in the prior quarter.
• Over five years, Tax Provisions peaked at $57.3 million in Q2 2025 and troughed at -$17.3 million in Q4 2022.
• A 5-year average of $18.4 million and a median of $14.8 million in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2022 — Tax Provisions tumbled 99.5% — and 2024, when it soared 4364.89%.
• Tracing BMRN's Tax Provisions over 5 years: stood at -$17.3 million in 2022, then jumped by 93.95% to -$1.0 million in 2023, then surged by 4364.89% to $44.7 million in 2024, then sank by 56.55% to $19.4 million in 2025, then surged by 83.71% to $35.7 million in 2026.
• Business Quant data shows BMRN's Tax Provisions at $35.7 million in Q1 2026, $19.4 million in Q4 2025, and $4.4 million in Q3 2025.